Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria | Zendy

Martín E. Stryjewski | Zendy; W. O'Riordan | Zendy; William K. Lau | Zendy; Francis D. Pien | Zendy; Lala M. Dunbar | Zendy; M Vallee | Zendy; Vance G. Fowler | Zendy; Vivian H. Chu | Zendy; Eden Adekola Torimiro Spencer | Zendy; Steven L. Barriere | Zendy; Michael M. Kitt | Zendy; C. H. Cabell | Zendy; G. Ralph Corey | Zendy

Open Access

Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria

Author(s) -

Martín E. Stryjewski,

W. O'Riordan,

William K. Lau,

Francis D. Pien,

Lala M. Dunbar,

M Vallee,

Vance G. Fowler,

Vivian H. Chu,

Eden Adekola Torimiro Spencer,

Steven L. Barriere,

Michael M. Kitt,

C. H. Cabell,

G. Ralph Corey

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/429914

Subject(s) - medicine , soft tissue , gram positive bacterial infections , gram negative bacterial infections , bacteria , microbiology and biotechnology , surgery , antibiotics , biology , genetics

Telavancin, a novel lipoglycopeptide, exerts concentration-dependent, rapid bactericidal activity on account of its multiple mechanisms of action. Telavancin is highly active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate, and vancomycin-resistant strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research